Ipsen presents new neurological data at TOXINS 2026

Ipsen presented 14 abstracts at TOXINS 2026, including an interim EPITOME analysis reporting that 45.7% of stroke survivors with paresis developed post‑stroke spasticity within one year; the company also cited evidence that under 1% of stroke survivors receive BoNT‑A treatment for spasticity in routine practice.

Ipsen presented a set of data at TOXINS 2026 in Madrid that covered multiple movement disorders, including post‑stroke spasticity, cervical dystonia and blepharospasm. The company highlighted an interim analysis from the multi‑country EPITOME epidemiology study, which uses a remote Post‑stroke Spasticity Monitoring Questionnaire to detect early signs of spasticity after first stroke. Ipsen also referenced published real‑world evidence noting that fewer than 1% of stroke survivors receive botulinum neurotoxin type A treatment for spasticity in routine practice. Key findings: - Ipsen presented 14 abstracts across multiple movement disorder indications at TOXINS 2026. - An interim EPITOME analysis reported that 45.7% of stroke survivors with paresis developed post‑stroke spasticity within one year of their stroke. - Cited real‑world evidence indicates under 1% of stroke survivors receive BoNT‑A treatment for spasticity in routine clinical practice. Summary: The presented data highlight persistent care gaps in the detection and treatment of post‑stroke spasticity and emphasize remote monitoring as a current research focus. The EPITOME study is ongoing and additional results beyond the interim analysis are pending. Undetermined at this time.